CANDACE MUSGROVE: Open Payments
NPI 1982239141 · DOUGLAS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,604 in 42 payments from 15 companies in 2025. Trend: 2023 $592 · 2024 $1,390 · 2025 $1,604
Long term medical supply or device loan: $1,000Food & beverage: $604
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 19 | $1,088 |
| Exelixis Inc. | 4 | $95 |
| Daiichi Sankyo Inc. | 4 | $95 |
| Fennec Pharmaceuticals, Inc. | 2 | $48 |
| Merck Sharp & Dohme LLC | 2 | $48 |
| JAZZ PHARMACEUTICALS INC. | 1 | $33 |
| Geron Corporation | 2 | $31 |
| Astellas Pharma US Inc | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Janssen Biotech, Inc. | 1 | $21 |
Products named: KISQALI, CABOMETYX, INJECTAFER, Fyarro, KEYTRUDA, DATROWAY, SCEMBLIX, ZEPZELCA.
Industry payments across GA — which companies pay providers there.
